WO2000004881A1 - Preparacion farmaceutica oral de un compuesto de actividad antifungica y procedimiento para su preparacion - Google Patents
Preparacion farmaceutica oral de un compuesto de actividad antifungica y procedimiento para su preparacion Download PDFInfo
- Publication number
- WO2000004881A1 WO2000004881A1 PCT/ES1999/000230 ES9900230W WO0004881A1 WO 2000004881 A1 WO2000004881 A1 WO 2000004881A1 ES 9900230 W ES9900230 W ES 9900230W WO 0004881 A1 WO0004881 A1 WO 0004881A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- pharmaceutical preparation
- oral pharmaceutical
- hydrophilic polymer
- preparation according
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
Definitions
- the present invention relates to an oral pharmaceutical composition
- an oral pharmaceutical composition comprising a compound with antifungal activity and in which the problems of low bioavailability caused by the poor solubility of the antifungal compounds in aqueous medium are solved.
- the present invention also relates to a process for obtaining said oral pharmaceutical preparation that presents improvements over conventional procedures.
- solubility of a compound can be increased by incorporating it into a hydrophilic polymer and applying said mixture on an inert core.
- a formulation that significantly improves the bioavailability of the compound is obtained.
- EP 658 103 (published in Spain as ES 2 097 536 T3) describes pellets of itraconazole and saperconazole prepared on the basis of this technology. It describes the preparation of a solution in methylene chloride and ethanol of the antifungal compound and the polymer hydrophilic hydroxypropyl methylcellulose (HPMC) and is nebulized in a fluid bed on inert cores of size between 600-700 ⁇ m. Once the fogging process is finished, the granules are dried in the same equipment for ten minutes at a temperature of 50-55DC, but subsequently they must be placed in a vacuum dryer for about 36 hours at a temperature of 80DC.
- HPMC polymer hydrophilic hydroxypropyl methylcellulose
- the dried cores are screened and subjected to a second coating process to form a second layer from a solution of polyethylene glycol 20000 (PEG 20000) in methylene chloride and ethanol in a fluid bed.
- PEG 20000 polyethylene glycol 20000
- the granules are dried in the equipment for 10 minutes at 50-55DC and subsequently they are supplied with dry air at 20-25DC for 5-15 minutes. After the drying process is stored in appropriate containers.
- EP 658 103 it is stated that the second coating layer with PEG 20000, sealant coating layer, is applied in order to prevent the pellets from sticking and that an inert core size between 600-700 ⁇ m is essential in order to avoid problems of drying and aggregation of pellets.
- an inert core size between 600-700 ⁇ m is essential in order to avoid problems of drying and aggregation of pellets.
- a larger size of inert cores represents a smaller specific surface area whereby the coating layers must be very thick and therefore difficult to dry, while an inert core size that is too small results in a coating layer. Thin, easy to dry but susceptible to agglomeration phenomena during the coating phase.
- an oral pharmaceutical formulation and a working method have been developed that allows solving the problems of solubility, drying and Bioavailability of pellets of antifungal compounds.
- the new formulation object of the present invention is characterized as spherical granules comprising an inert core coated by a single active loading layer comprising an antifungal compound.
- the coating process on inert cores is carried out by nebulizing a solution of antifungal compound.
- the oral pharmaceutical preparation of the present invention comprises: a / an inert core b / a soluble active layer obtained from a solution comprising:
- the active substances with antifungal activity included in the scope of the present invention are itraconazole, (D) -cis-4- [4- [4- [4- [4- [[2- (2, 4-dichlorophenyl) -2- (1H -1, 2, 4-triazol-l-ylmethyl) -1, 3-dioxolan-4-yl] methoxy] phenyl] -1-piperazinyl] phenyl] -2,4-dihydro -2- (1- methylpropyl) - 3H-1, 2, 4-triazol-3-one, and saperconazole, (D) - cis-4- [4- [4- [4- [4- [4- [[2- (2, 4-difluorophenyl) -2- (1H -1, 2, 4-triazol-1-ylmethyl) -1, 3-dioxolan-4-yl] methoxy] phenyl] -1-piperazinyl] phenyl
- the inert nuclei are neutral spherical microgranules that can have two or more of the following substances in their composition: sorbitol, mannitol, sucrose, starch, microcrystalline cellulose, lactose, glucose, trehalose, maltitol and fructose.
- Their size is between 50-600 ⁇ m, preferably between 500-600 ⁇ m.
- the solution to be nebulized on inert nuclei is formed by the active ingredient. with antifungal activity dissolved in a mixture of organic solvents formed by methylene chloride and ethanol, in which the hydrophilic polymer and a surfactant are dissolved.
- the hydrophilic polymer can be HPMC, hydroxypropylcellulose (HPC), polyvinylpyrrolidone (PVP), methacrylates etc.
- the weight to weight ratio (p: p) between the antifungal agent and the polymer is of the order [(1: 1) (1: 3)].
- the nonionic surfactant can be esters of propylene glycol, esters of glycerol, sorbitan (mono-di-tri-) acetylated, sucrose (mono, di-tri) acetylated, polyoxyethylene sorbital fatty acid esters, polyoxyethylene alkyl fatty chain esters, polyoxyethylene-polyoxypropylene copolymers .. etc.
- the weight to weight ratio between the antifungal agent and the surfactant is of the order [(1,5: 1) - (29: 1)].
- Another object of the present invention is a manufacturing process of the galenic formulations object of the present invention.
- the coating solution is nebulized to obtain a single layer on the neutral pellets of a size between 50-600 ⁇ m, preferably (500-600) ⁇ m, in a fluid bed.
- the fogging speed is constant and the temperature is maintained at 45DC.
- the pellets they are kept in the equipment for 15 minutes at a temperature of 45DC as the last drying phase.
- a fluid bed is used in which the coating process is carried out. It is not necessary to use a second equipment to dry the coated granules, but a short drying stage (15 minutes at 45DC) in the same equipment after finishing the single layer coating stage is sufficient. In this way, not only is the process time shorter than that of EP 658 103, since it is not necessary to introduce the pellets or granules into a vacuum dryer, but at the same time avoiding having to subject them to extreme temperatures 80DC for 36 hours.
- the temperature at which the cores are subjected is 45DC, lower than the one used in EP 658 103, which in turn turns out to be a beneficial factor in controlling chemical stability. of the active principle as well as avoiding the disadvantage already mentioned in EP 658 103 that high temperatures can accelerate drying of granules with risk of forming non-uniform layers and of great porosity.
- the fogging speed is a factor to be taken into account in order to obtain a greater efficiency of the process.
- the speed is slow, product losses can occur due to drying of the mist itself.
- the coating speed of the present invention is lower and remains constant throughout the process.
- the technology described in EP 658 103 has been improved since it works with inert cores of smaller size than those described in EP 658 103, without causing agglomeration of the granules.
Abstract
Description
Claims
Priority Applications (25)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP99931261A EP1103252B1 (en) | 1998-07-21 | 1999-07-20 | Pharmaceutical oral preparation of a compound having an antifungic activity, and preparation method |
MXPA01000681A MXPA01000681A (es) | 1998-07-21 | 1999-07-20 | Preparacion farmaceutica oral de un compuesto de actividad antifungica y procedimiento para su preparacion. |
EEP200100041A EE04415B1 (et) | 1998-07-21 | 1999-07-20 | Antimükootilist toimet omava ühendi farmatseutiline peroraalne preparaat ja selle valmistamismeetod |
AU47821/99A AU750730B2 (en) | 1998-07-21 | 1999-07-20 | Pharmaceutical oral preparation of a compound having an antifungic activity, and preparation method |
DK99931261T DK1103252T3 (da) | 1998-07-21 | 1999-07-20 | Oral farmaceutisk sammensætning af en forbindelse med en afsvampningsaktivitet og fremgangsmåde til fremstilling deraf |
US09/744,322 US6737082B1 (en) | 1998-07-21 | 1999-07-20 | Pharmaceutical oral preparation of a compound having an antifungic activity, and preparation method |
JP2000560874A JP4190732B2 (ja) | 1998-07-21 | 1999-07-20 | 抗真菌活性化合物を含む経口医薬組成物およびその製法 |
KR1020017000783A KR100572135B1 (ko) | 1998-07-21 | 1999-07-20 | 항진균 활성을 갖는 화합물의 경구용 약제 및 이의 제조방법 |
UA2001021260A UA64009C2 (en) | 1998-07-21 | 1999-07-20 | Pharmaceutical composition comprising antifungal agent and method for its production |
PL99345625A PL194740B1 (pl) | 1998-07-21 | 1999-07-20 | Doustna kompozycja farmaceutyczna w postaci peletek zawierająca związek o działaniu przeciwgrzybicznym i sposób jej wytwarzania |
HU0103708A HU228895B1 (en) | 1998-07-21 | 1999-07-20 | Pharmaceutical oral preparation of a compound having an antifungic activity, and preparation method |
MEP-267/08A MEP26708A (en) | 1998-07-21 | 1999-07-20 | Pharmaceutical oral preparation of a compound having an antifungic activity, and preparation method |
SK86-2001A SK283279B6 (sk) | 1998-07-21 | 1999-07-20 | Orálny farmaceutický prostriedok protihubovo účinnej zlúčeniny a spôsob jeho prípravy |
IL14091099A IL140910A (en) | 1998-07-21 | 1999-07-20 | An oral pharmaceutical preparation of a compound with antifungal activity and a method of preparation |
CA002337509A CA2337509C (en) | 1998-07-21 | 1999-07-20 | Pharmaceutical oral preparation of a compound having an antifungic activity, and preparation method |
YUP-39/01A RS50063B (sr) | 1998-07-21 | 1999-07-20 | Oralni farmaceutski preparat sa fungicidnim dejstvom i postupak za njegovo pripremanje |
SI9930282T SI1103252T1 (en) | 1998-07-21 | 1999-07-20 | Pharmaceutical oral preparation of a compound having an antifungic activity, and preparation method |
NZ509886A NZ509886A (en) | 1998-07-21 | 1999-07-20 | Pharmaceutical oral preparation of either itraconazole or saperconazole having antifungic activity |
DE69905905T DE69905905T2 (de) | 1998-07-21 | 1999-07-20 | Orale pharmazeutische zusammensetzung enthaltend einen wirkstoff mit antimykotischer wirkung und verfahren zu ihrer herstellung |
AT99931261T ATE234077T1 (de) | 1998-07-21 | 1999-07-20 | Orale pharmazeutische zusammensetzung enthaltend einen wirkstoff mit antimykotischer wirkung und verfahren zu ihrer herstellung |
BR9912300-2A BR9912300A (pt) | 1998-07-21 | 1999-07-20 | Composição farmacêutica oral de um composto tendo atividade antifúngica e método para a sua preparação |
NO20010289A NO320054B1 (no) | 1998-07-21 | 2001-01-17 | Oral farmasoytisk sammensetning med en forbindelse som har antisopp aktivitet og en metode for dens fremstilling |
HR20010128A HRP20010128B1 (en) | 1998-07-21 | 2001-02-21 | Pharmaceutical oral preparation of a compound having an antifungic activity, and preparation method |
BG105282A BG65187B1 (bg) | 1998-07-21 | 2001-02-21 | Фармацевтичен състав за орално приложение, съдържащ съединения с антифунгицидно действие, и метод за получаването му |
HK01108330A HK1037531A1 (en) | 1998-07-21 | 2001-11-27 | Pharmaceutical oral preparation of a compound having an antifungic acitivity, and preparation method |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ESP9801539 | 1998-07-21 | ||
ES009801539A ES2157731B1 (es) | 1998-07-21 | 1998-07-21 | Preparacion farmaceutica oral de un compuesto de actividad antifungica y procedimiento para su preparacion. |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000004881A1 true WO2000004881A1 (es) | 2000-02-03 |
Family
ID=8304581
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/ES1999/000230 WO2000004881A1 (es) | 1998-07-21 | 1999-07-20 | Preparacion farmaceutica oral de un compuesto de actividad antifungica y procedimiento para su preparacion |
Country Status (31)
Country | Link |
---|---|
US (1) | US6737082B1 (es) |
EP (1) | EP1103252B1 (es) |
JP (1) | JP4190732B2 (es) |
KR (1) | KR100572135B1 (es) |
AT (1) | ATE234077T1 (es) |
AU (1) | AU750730B2 (es) |
BG (1) | BG65187B1 (es) |
BR (1) | BR9912300A (es) |
CA (1) | CA2337509C (es) |
CZ (1) | CZ291938B6 (es) |
DE (1) | DE69905905T2 (es) |
DK (1) | DK1103252T3 (es) |
EE (1) | EE04415B1 (es) |
ES (2) | ES2157731B1 (es) |
HK (1) | HK1037531A1 (es) |
HR (1) | HRP20010128B1 (es) |
HU (1) | HU228895B1 (es) |
IL (1) | IL140910A (es) |
ME (1) | MEP26708A (es) |
MX (1) | MXPA01000681A (es) |
NO (1) | NO320054B1 (es) |
NZ (1) | NZ509886A (es) |
PL (1) | PL194740B1 (es) |
PT (1) | PT1103252E (es) |
RS (1) | RS50063B (es) |
RU (1) | RU2209628C2 (es) |
SK (1) | SK283279B6 (es) |
TR (1) | TR200100177T2 (es) |
UA (1) | UA64009C2 (es) |
WO (1) | WO2000004881A1 (es) |
ZA (1) | ZA200101293B (es) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8026286B2 (en) | 1999-12-23 | 2011-09-27 | Bend Research, Inc. | Pharmaceutical compositions providing enhanced drug concentrations |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE262799T1 (de) * | 1996-01-31 | 2004-04-15 | Univ South Alabama | Lebensmittel und vitamin herstellungen mit natürlichem isomeren von reduzierten folaten |
US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
FR2842736B1 (fr) | 2002-07-26 | 2005-07-22 | Flamel Tech Sa | Formulation pharmaceutique orale sous forme d'une pluralite de microcapsules permettant la liberation prolongee de principe(s) actif(s) peu soluble(s) |
US20040115287A1 (en) * | 2002-12-17 | 2004-06-17 | Lipocine, Inc. | Hydrophobic active agent compositions and methods |
DE60312636T3 (de) * | 2003-01-14 | 2014-12-24 | Acino Pharma Ag | Bioaequivalente Zusammensetzung in der Form einer festen Dispersion enthaltend Itraconazol und ein hydrophiles Polymer |
DK1438960T4 (da) * | 2003-01-14 | 2013-03-25 | Cimex Pharma Ag | Sammensætning af itraconazol dispergeret i en hydrofil polymer med forhøjet biotilgængelighed |
FR2852607B1 (fr) * | 2003-03-20 | 2006-07-14 | Procede de fabrication de microspheres de sucre de petite taille, les microspheres susceptibles d'etre obtenues par ce procede et leurs applications | |
FR2857591B1 (fr) * | 2003-07-17 | 2007-11-02 | Ethypharm Sa | Particules comprenant un principe actif sous forme de co-precipite |
WO2005011702A1 (en) * | 2003-07-17 | 2005-02-10 | Tibotec Pharmaceuticals Ltd. | Process for preparing particles containing an antiviral |
FR2883179B1 (fr) | 2005-03-18 | 2009-04-17 | Ethypharm Sa | Comprime enrobe |
EP2404602A1 (en) | 2005-08-22 | 2012-01-11 | The Johns Hopkins University | Hedgehog pathway antagonists to treat cancer |
CN101283984B (zh) * | 2007-04-12 | 2010-05-26 | 永胜药品工业股份有限公司 | 高生物使用率的经杀真菌剂和聚合物涂覆的核心微粒状物 |
US11304960B2 (en) | 2009-01-08 | 2022-04-19 | Chandrashekar Giliyar | Steroidal compositions |
EP2542222A2 (de) * | 2010-03-05 | 2013-01-09 | Basf Se | Schmelzüberzogene arzneiformen |
US20180153904A1 (en) | 2010-11-30 | 2018-06-07 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US9358241B2 (en) | 2010-11-30 | 2016-06-07 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US9034858B2 (en) | 2010-11-30 | 2015-05-19 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US20120148675A1 (en) | 2010-12-10 | 2012-06-14 | Basawaraj Chickmath | Testosterone undecanoate compositions |
WO2016033549A2 (en) | 2014-08-28 | 2016-03-03 | Lipocine Inc. | (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE |
US9498485B2 (en) | 2014-08-28 | 2016-11-22 | Lipocine Inc. | Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters |
MA40982A (fr) * | 2014-11-19 | 2017-09-26 | Biogen Ma Inc | Formulation de bille pharmaceutique comprenant du fumarate de diméthyle |
RU2017141029A (ru) * | 2015-05-25 | 2019-06-25 | Сан Фармасьютикал Индастриз Лимитед | Фармацевтическая пероральная композиция изотретиноина для применения один раз в сутки |
US10137111B2 (en) | 2016-08-11 | 2018-11-27 | Adamis Pharmaceuticals Corporation | Drug compositions comprising an anti-parasitic and proton pump inhibitor |
JP2020503269A (ja) | 2016-11-28 | 2020-01-30 | リポカイン インコーポレーテッド | 経口ウンデカン酸テストステロン療法 |
WO2019113493A1 (en) | 2017-12-08 | 2019-06-13 | Adamis Pharmaceuticals Corporation | Drug compositions |
CN112313289A (zh) * | 2018-04-27 | 2021-02-02 | 凸版印刷株式会社 | 缓释性复合颗粒、缓释性复合颗粒的制造方法、干燥粉体、以及壁纸 |
WO2023118082A1 (en) * | 2021-12-22 | 2023-06-29 | Palau Pharma, S.L.U. | Multiparticulate albaconazole composition |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998000116A1 (en) * | 1996-06-28 | 1998-01-08 | Schering Corporation | Oral composition comprising a triazole antifungal compound |
WO1998042318A1 (en) * | 1997-03-26 | 1998-10-01 | Janssen Pharmaceutica N.V. | Pellets having a core coated with an antifungal and a polymer |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4267179A (en) * | 1978-06-23 | 1981-05-12 | Janssen Pharmaceutica, N.V. | Heterocyclic derivatives of (4-phenylpiperazin-1-yl-aryloxymethyl-1,3-dioxolan-2-yl)methyl-1H-imidazoles and 1H-1,2,4-triazoles |
US4916134A (en) * | 1987-03-25 | 1990-04-10 | Janssen Pharmacuetica N.V. | 4-[4-[4-[4-[[2-(2,4-difluorophenyl)-2-(1H-azolylmethyl)-1,3-dioxolan-4-yl]me]phenyl]-1-piperazinyl]phenyl]triazolones |
IE61651B1 (en) * | 1990-07-04 | 1994-11-16 | Zambon Spa | Programmed release oral solid pharmaceutical dosage form |
PH30929A (en) * | 1992-09-03 | 1997-12-23 | Janssen Pharmaceutica Nv | Beads having a core coated with an antifungal and a polymer. |
US5567441A (en) * | 1995-03-24 | 1996-10-22 | Andrx Pharmaceuticals Inc. | Diltiazem controlled release formulation |
NZ330739A (en) * | 1996-05-20 | 1999-06-29 | Janssen Pharmaceutica Nv | Particulate solid dispersion of itraconazole and a water soluble polymer |
CA2255663C (en) * | 1996-05-24 | 2002-08-20 | Schering Corporation | Antifungal composition with enhanced bioavailability |
DE19626924C2 (de) * | 1996-07-04 | 1999-08-19 | Epazon B V | Gerät zur Bereitstellung eines Atemgases |
-
1998
- 1998-07-21 ES ES009801539A patent/ES2157731B1/es not_active Expired - Fee Related
-
1999
- 1999-07-20 IL IL14091099A patent/IL140910A/en not_active IP Right Cessation
- 1999-07-20 RU RU2001104894/14A patent/RU2209628C2/ru not_active IP Right Cessation
- 1999-07-20 BR BR9912300-2A patent/BR9912300A/pt not_active Application Discontinuation
- 1999-07-20 CA CA002337509A patent/CA2337509C/en not_active Expired - Fee Related
- 1999-07-20 UA UA2001021260A patent/UA64009C2/uk unknown
- 1999-07-20 JP JP2000560874A patent/JP4190732B2/ja not_active Expired - Fee Related
- 1999-07-20 SK SK86-2001A patent/SK283279B6/sk not_active IP Right Cessation
- 1999-07-20 DE DE69905905T patent/DE69905905T2/de not_active Expired - Lifetime
- 1999-07-20 MX MXPA01000681A patent/MXPA01000681A/es active IP Right Grant
- 1999-07-20 PT PT99931261T patent/PT1103252E/pt unknown
- 1999-07-20 HU HU0103708A patent/HU228895B1/hu not_active IP Right Cessation
- 1999-07-20 CZ CZ2001175A patent/CZ291938B6/cs not_active IP Right Cessation
- 1999-07-20 NZ NZ509886A patent/NZ509886A/xx not_active IP Right Cessation
- 1999-07-20 ES ES99931261T patent/ES2194480T3/es not_active Expired - Lifetime
- 1999-07-20 EE EEP200100041A patent/EE04415B1/xx not_active IP Right Cessation
- 1999-07-20 KR KR1020017000783A patent/KR100572135B1/ko not_active IP Right Cessation
- 1999-07-20 WO PCT/ES1999/000230 patent/WO2000004881A1/es not_active Application Discontinuation
- 1999-07-20 ME MEP-267/08A patent/MEP26708A/xx unknown
- 1999-07-20 AT AT99931261T patent/ATE234077T1/de active
- 1999-07-20 TR TR2001/00177T patent/TR200100177T2/xx unknown
- 1999-07-20 DK DK99931261T patent/DK1103252T3/da active
- 1999-07-20 RS YUP-39/01A patent/RS50063B/sr unknown
- 1999-07-20 US US09/744,322 patent/US6737082B1/en not_active Expired - Fee Related
- 1999-07-20 AU AU47821/99A patent/AU750730B2/en not_active Ceased
- 1999-07-20 EP EP99931261A patent/EP1103252B1/en not_active Expired - Lifetime
- 1999-07-20 PL PL99345625A patent/PL194740B1/pl not_active IP Right Cessation
-
2001
- 2001-01-17 NO NO20010289A patent/NO320054B1/no not_active IP Right Cessation
- 2001-02-15 ZA ZA200101293A patent/ZA200101293B/en unknown
- 2001-02-21 BG BG105282A patent/BG65187B1/bg unknown
- 2001-02-21 HR HR20010128A patent/HRP20010128B1/xx not_active IP Right Cessation
- 2001-11-27 HK HK01108330A patent/HK1037531A1/xx not_active IP Right Cessation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998000116A1 (en) * | 1996-06-28 | 1998-01-08 | Schering Corporation | Oral composition comprising a triazole antifungal compound |
WO1998042318A1 (en) * | 1997-03-26 | 1998-10-01 | Janssen Pharmaceutica N.V. | Pellets having a core coated with an antifungal and a polymer |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8026286B2 (en) | 1999-12-23 | 2011-09-27 | Bend Research, Inc. | Pharmaceutical compositions providing enhanced drug concentrations |
US8501231B2 (en) | 1999-12-23 | 2013-08-06 | Bend Research, Inc. | Pharmaceutical compositions providing enhanced drug concentrations |
US8796341B2 (en) | 1999-12-23 | 2014-08-05 | Bend Research, Inc. | Pharmaceutical compositions providing enhanced drug concentrations |
US8980321B2 (en) | 1999-12-23 | 2015-03-17 | Bend Research, Inc. | Pharmaceutical compositions providing enhanced drug concentrations |
US9457095B2 (en) | 1999-12-23 | 2016-10-04 | Bend Research, Inc. | Pharmaceutical compositions providing enhanced drug concentrations |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2000004881A1 (es) | Preparacion farmaceutica oral de un compuesto de actividad antifungica y procedimiento para su preparacion | |
ES2761407T3 (es) | Forma de dosificación rápidamente dispersable de topiramato | |
US6673373B2 (en) | Antifungal formulation and the methods for manufacturing and using the same | |
WO1999006032A2 (es) | Preparacion farmaceutica oral que comprende un compuesto de actividad antiulcerosa y procedimiento para su obtencion | |
JP2002520351A (ja) | 抗菌・カビ剤及びポリマーを被覆したコアを有するペレット | |
HU225425B1 (en) | Microgranules containing cisplatin | |
ES2756711T3 (es) | Formulaciones estabilizadas de compuestos del SNC | |
US8889728B2 (en) | Stable pharmaceutical compositions of carvedilol | |
ES2287813T3 (es) | Microcomprimidos recubertos de liberacion prolongada de clorhidrato de venlafaxina. | |
WO2017182852A1 (en) | Extended release liquid compositions of guanfacine | |
KR20090016612A (ko) | 피페리디노알칸올 및 충혈완화제의 복합제를 포함하는 약학조성물 | |
ES2898456T3 (es) | Composición farmacéutica que comprende un agente antifúngico triazol y método de preparación de la misma | |
US20070148240A1 (en) | Oral formulation containing itraconazole and methods for manufacturing and using the same | |
ES2896150T3 (es) | Composiciones líquidas de liberación prolongada de guaifenesina | |
WO1999001129A1 (en) | Process for preparing controlled-release dihydropyridine compositions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: P-39/01 Country of ref document: YU |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2337509 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: PV2001-175 Country of ref document: CZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 140910 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 862001 Country of ref document: SK |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020017000783 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2001/000681 Country of ref document: MX Ref document number: 2001/00177 Country of ref document: TR |
|
ENP | Entry into the national phase |
Ref document number: 2000 560874 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 509886 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999931261 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001/01293 Country of ref document: ZA Ref document number: 200101293 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 47821/99 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 1999 105282 Country of ref document: BG Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: P20010128A Country of ref document: HR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09744322 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: PV2001-175 Country of ref document: CZ |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1999931261 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020017000783 Country of ref document: KR |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
WWG | Wipo information: grant in national office |
Ref document number: 47821/99 Country of ref document: AU |
|
WWG | Wipo information: grant in national office |
Ref document number: 1999931261 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: PV2001-175 Country of ref document: CZ |
|
WWR | Wipo information: refused in national office |
Ref document number: 1020017000783 Country of ref document: KR |